L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Alopecia
- 5min
- May. 2022
- Supported by
Therapeutic classes inducing this adverse event
Chemotherapy, SMO inhibitor, BRAF inhibitor, Antiangiogenic agent, MEK inhibitor, EGFR inhibitor, Hormone therapy, Cyclin-dependent kinase 4/6 inhibitor
CTCAE V5.0
Hair loss of up to 50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be required to cover the hair loss but it does not require a wig or hair piece to camouflage
SIMPLIFIED GRADING
Not obvious, easy to camouflage
REFERENCES
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Hair loss of >50% normal for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact.
SIMPLIFIED GRADING
Readily apparent OR Psychosocial impact.
REFERENCES
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events